Key result
Transcatheter aortic valve implantation in bicuspid aortic valve patients demonstrated comparable 30-day mortality to non-bicuspid patients.
Why the study?
Does transcatheter aortic valve implantation (TAVI) provide comparable safety and efficacy in patients with bicuspid aortic valves compared to non-bicuspid aortic valves?
Systematic Review (n=166)
Does transcatheter aortic valve implantation (TAVI) provide comparable safety and efficacy in patients with bicuspid aortic valves compared to non-bicuspid aortic valves?
TAVI appears to be a feasible and safe treatment modality for patients with bicuspid aortic valves, yielding short- and medium-term outcomes comparable to those seen in non-bicuspid patients.
Answers are grounded in this paper and cite their sources.
Supports TAVI in bicuspid aortic valves; extends trial evidence to this anatomy.
PURPOSE: To elucidate the performance of transcatheter aortic valve implantation (TAVI) in bicuspid aortic valve (BAV) patients through a systematic review and meta-analysis. METHODS: A systematic literature review was performed by searching eligible articles in PubMed, Medline, EMBASE, Google Scholar and CNKI. Meta-analysis of included case-control/cohort studies was further conducted. Relative risks (RRs) and the corresponding 95% confidence intervals (CIs) were used to compare clinical outcomes of BAV patients and non-BAV patients. RESULTS: A total of 17 articles including eight case reports, four case series and five case-control/cohort studies with 166 BAV patients were analyzed. Device success rate achieved for TAVI in this cohort of BAV patients was 95.2%. The 30-day mortality rate was 8.4%, and the medium-term (range from 6 months to 2 years) mortality rate reported was 17.9%. Overall, the performance of TAVI in BAV patients was comparable to that in non-BAV patients, as reported by the included case-control/cohort studies (30-day mortality rate: RR = 1.05, 95%CI 0.57-1.95, p = 0.87; Device success rate: RR = 1.00, 95%CI 0.95-1.05, p = 0.94; Incidence of moderate to severe paravalvular regurgitation: RR = 1.25, 95%CI 0.85-1.84, p = 0.25). CONCLUSION: The present study suggested that TAVI may be a feasible and safe treatment modality for BAV patients.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2016) conducted a systematic review in Bicuspid aortic valve (BAV) requiring transcatheter aortic valve implantation (n=166). Transcatheter Aortic Valve Implantation (TAVI) vs. Non-bicuspid aortic valve patients was evaluated on 30-day mortality rate (RR 1.05, 95% CI 0.57-1.95, p=0.87). Transcatheter aortic valve implantation in bicuspid aortic valve patients demonstrated comparable 30-day mortality to non-bicuspid patients.
Synapse has enriched 10 related papers. Consider them for comparative context: